Summary

The global protein engineering market was valued at $2,227.15 million in 2022 and is projected to reach $7,709.32 million by 2032, registering a CAGR of 13.2% from 2023 to 2032.
Protein engineering is the process by which a scientist alters the sequence of a protein by adding, deleting, or substituting nucleotides in the encoding gene to produce a modified protein that is better suited than the original protein for a given use or objective. There are two general strategies for protein engineering such as rational protein design and directed evolution. In rational protein design, a scientist modifies a protein by using in-depth understanding of its structure and function. Since site-directed mutagenesis techniques are well-established, this generally has the benefit of being affordable and simple to implement technically.

In addition, in directed evolution, a protein is subjected to random mutagenesis, such as sequence saturation mutagenesis or error-prone PCR mutagenesis, and variants with desirable features are chosen by a selection regime. Then, more iterations of selection and mutation are used. In general, this approach outperforms rational design since it emulates natural evolution.
The major factors driving the growth of protein engineering market are the growing demand for biopharmaceuticals, including monoclonal antibodies, vaccines, and therapeutic proteins. Protein engineering plays a crucial role in optimizing the properties of these biologics, improving their efficacy, safety, and specificity, which drive growth of the protein engineering market. In addition, rising investments from both public and private sectors in R&D activities related to protein engineering contribute to the market growth.
Furthermore, continuous advancements in protein engineering technologies, such as CRISPR-based approaches, directed evolution, and computational protein design, are driving the market growth. These technologies enable more precise and efficient manipulation of protein structures and functions.

Protein engineering accelerates drug development by providing tools to design and modify proteins for therapeutic purposes. In addition, rise in prevalence of chronic diseases, such as cancer, autoimmune disorders, and metabolic diseases, fuels the demand for innovative therapeutic solutions as engineered proteins offer targeted and personalized treatment options.
The protein engineering market is segmented into product, protein type, technology type, end user, and region. By product, the market is segregated into instruments, consumables, and software. By protein type, the market is classified into monoclonal antibodies, insulin, erythropoietin, interferon, and others. The others segment further includes interleukin, transforming growth factors, epidermal growth factors, tumor necrosis factor, stem cell factor, colony stimulating factors, growth factors, and coagulation factors. By technology type, the market is segregated into rational/ site directed mutagenesis, and irrational/ random mutagenesis.

By end user, the market is divided into pharmaceutical & biotechnological companies, academic & research institutes, and contract research organizations. Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (India, China, Japan, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Major key players that operate in the global protein engineering market are Agilent Technologies, Inc., Thermo Fisher Scientific Inc., Takara Holdings, Inc., Promega Corporation, New England Biolabs, Jena Bioscience GmbH, Danaher Corporation, Creative Biolabs, Amgen, Inc., and Bio-Rad laboratories, Inc. The key players have adopted strategies such as product launch, partnership, and acquisition to expand their product portfolio

Key Benefits For Stakeholders
●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the protein engineering market analysis from 2022 to 2032 to identify the prevailing protein engineering market opportunities.
●The market research is offered along with information related to key drivers, restraints, and opportunities.
●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
●In-depth analysis of the protein engineering market segmentation assists to determine the prevailing market opportunities.
●Major countries in each region are mapped according to their revenue contribution to the global market.
●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
●The report includes the analysis of the regional as well as global protein engineering market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:
● Quarterly Update and* (only available with a corporate license, on listed price)
● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
● Free Upcoming Version on the Purchase of Five and Enterprise User License.
● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
● Free data Pack on the Five and Enterprise User License. (Excel version of the report)
● Free Updated report if the report is 6-12 months old or older.
● 24-hour priority response*
● Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
● Additional company profiles with specific to client's interest
● Expanded list for Company Profiles
● Historic market data
Key Market Segments
By End User
● Pharmaceutical and Biotechnology Companies
● Academic Research Institutes
● Contract Research Organizations
By Product
● Instruments
● Consumables
● Software
By Technology Type
● Rational or Site Directed Mutagenesis
● Irrational or Random Mutagenesis
By Protein Type
● Monoclonal Antibodies
● Insulin
● Erythropoietin
● Interferon
● Others
By Region
● North America
○ U.S.
○ Canada
○ Mexico
● Europe
○ Germany
○ France
○ UK
○ Italy
○ Spain
○ Rest of Europe
● Asia-Pacific
○ Japan
○ China
○ India
○ Australia
○ South Korea
○ Rest of Asia-Pacific
● LAMEA
○ Brazil
○ Saudi Arabia
○ South Africa
○ Rest of LAMEA
● Key Market Players
○ Agilent Technologies, Inc.
○ Promega Corporation
○ New England Biolabs, Inc.
○ Danaher Corporation
○ Bio-Rad Laboratories, Inc.
○ Amgen, Inc.
○ TAKARA HOLDINGS INC.
○ Thermo Fisher Scientific Inc.
○ Creative Biolabs Limited
○ Jena Bioscience GmbH

ページTOPに戻る

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Moderate bargaining power of suppliers
3.3.2. Moderate threat of new entrants
3.3.3. Moderate threat of substitutes
3.3.4. High intensity of rivalry
3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increasing research & development activities in the biopharmaceutical industry
3.4.1.2. Technological advancements in protein engineering
3.4.1.3. Increase in developmental strategies in protein engineering by key players
3.4.2. Restraints
3.4.2.1. High cost and maintenance of protein engineering systems
3.4.3. Opportunities
3.4.3.1. Growth in opportunities in emerging markets
CHAPTER 4: PROTEIN ENGINEERING MARKET, BY PRODUCT
4.1. Overview
4.1.1. Market size and forecast
4.2. Instruments
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Consumables
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Software
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: PROTEIN ENGINEERING MARKET, BY TECHNOLOGY TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Rational or Site Directed Mutagenesis
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Irrational or Random Mutagenesis
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE
6.1. Overview
6.1.1. Market size and forecast
6.2. Monoclonal Antibodies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Insulin
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Erythropoietin
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
6.5. Interferon
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by region
6.5.3. Market share analysis by country
6.6. Others
6.6.1. Key market trends, growth factors and opportunities
6.6.2. Market size and forecast, by region
6.6.3. Market share analysis by country
CHAPTER 7: PROTEIN ENGINEERING MARKET, BY END USER
7.1. Overview
7.1.1. Market size and forecast
7.2. Pharmaceutical and Biotechnology Companies
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Academic Research Institutes
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
7.4. Contract Research Organizations
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by region
7.4.3. Market share analysis by country
CHAPTER 8: PROTEIN ENGINEERING MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast By Region
8.2. North America
8.2.1. Key market trends, growth factors and opportunities
8.2.2. Market size and forecast, by Product
8.2.3. Market size and forecast, by Technology Type
8.2.4. Market size and forecast, by Protein Type
8.2.5. Market size and forecast, by End User
8.2.6. Market size and forecast, by country
8.2.6.1. U.S.
8.2.6.1.1. Market size and forecast, by Product
8.2.6.1.2. Market size and forecast, by Technology Type
8.2.6.1.3. Market size and forecast, by Protein Type
8.2.6.1.4. Market size and forecast, by End User
8.2.6.2. Canada
8.2.6.2.1. Market size and forecast, by Product
8.2.6.2.2. Market size and forecast, by Technology Type
8.2.6.2.3. Market size and forecast, by Protein Type
8.2.6.2.4. Market size and forecast, by End User
8.2.6.3. Mexico
8.2.6.3.1. Market size and forecast, by Product
8.2.6.3.2. Market size and forecast, by Technology Type
8.2.6.3.3. Market size and forecast, by Protein Type
8.2.6.3.4. Market size and forecast, by End User
8.3. Europe
8.3.1. Key market trends, growth factors and opportunities
8.3.2. Market size and forecast, by Product
8.3.3. Market size and forecast, by Technology Type
8.3.4. Market size and forecast, by Protein Type
8.3.5. Market size and forecast, by End User
8.3.6. Market size and forecast, by country
8.3.6.1. Germany
8.3.6.1.1. Market size and forecast, by Product
8.3.6.1.2. Market size and forecast, by Technology Type
8.3.6.1.3. Market size and forecast, by Protein Type
8.3.6.1.4. Market size and forecast, by End User
8.3.6.2. France
8.3.6.2.1. Market size and forecast, by Product
8.3.6.2.2. Market size and forecast, by Technology Type
8.3.6.2.3. Market size and forecast, by Protein Type
8.3.6.2.4. Market size and forecast, by End User
8.3.6.3. UK
8.3.6.3.1. Market size and forecast, by Product
8.3.6.3.2. Market size and forecast, by Technology Type
8.3.6.3.3. Market size and forecast, by Protein Type
8.3.6.3.4. Market size and forecast, by End User
8.3.6.4. Italy
8.3.6.4.1. Market size and forecast, by Product
8.3.6.4.2. Market size and forecast, by Technology Type
8.3.6.4.3. Market size and forecast, by Protein Type
8.3.6.4.4. Market size and forecast, by End User
8.3.6.5. Spain
8.3.6.5.1. Market size and forecast, by Product
8.3.6.5.2. Market size and forecast, by Technology Type
8.3.6.5.3. Market size and forecast, by Protein Type
8.3.6.5.4. Market size and forecast, by End User
8.3.6.6. Rest of Europe
8.3.6.6.1. Market size and forecast, by Product
8.3.6.6.2. Market size and forecast, by Technology Type
8.3.6.6.3. Market size and forecast, by Protein Type
8.3.6.6.4. Market size and forecast, by End User
8.4. Asia-Pacific
8.4.1. Key market trends, growth factors and opportunities
8.4.2. Market size and forecast, by Product
8.4.3. Market size and forecast, by Technology Type
8.4.4. Market size and forecast, by Protein Type
8.4.5. Market size and forecast, by End User
8.4.6. Market size and forecast, by country
8.4.6.1. Japan
8.4.6.1.1. Market size and forecast, by Product
8.4.6.1.2. Market size and forecast, by Technology Type
8.4.6.1.3. Market size and forecast, by Protein Type
8.4.6.1.4. Market size and forecast, by End User
8.4.6.2. China
8.4.6.2.1. Market size and forecast, by Product
8.4.6.2.2. Market size and forecast, by Technology Type
8.4.6.2.3. Market size and forecast, by Protein Type
8.4.6.2.4. Market size and forecast, by End User
8.4.6.3. India
8.4.6.3.1. Market size and forecast, by Product
8.4.6.3.2. Market size and forecast, by Technology Type
8.4.6.3.3. Market size and forecast, by Protein Type
8.4.6.3.4. Market size and forecast, by End User
8.4.6.4. Australia
8.4.6.4.1. Market size and forecast, by Product
8.4.6.4.2. Market size and forecast, by Technology Type
8.4.6.4.3. Market size and forecast, by Protein Type
8.4.6.4.4. Market size and forecast, by End User
8.4.6.5. South Korea
8.4.6.5.1. Market size and forecast, by Product
8.4.6.5.2. Market size and forecast, by Technology Type
8.4.6.5.3. Market size and forecast, by Protein Type
8.4.6.5.4. Market size and forecast, by End User
8.4.6.6. Rest of Asia-Pacific
8.4.6.6.1. Market size and forecast, by Product
8.4.6.6.2. Market size and forecast, by Technology Type
8.4.6.6.3. Market size and forecast, by Protein Type
8.4.6.6.4. Market size and forecast, by End User
8.5. LAMEA
8.5.1. Key market trends, growth factors and opportunities
8.5.2. Market size and forecast, by Product
8.5.3. Market size and forecast, by Technology Type
8.5.4. Market size and forecast, by Protein Type
8.5.5. Market size and forecast, by End User
8.5.6. Market size and forecast, by country
8.5.6.1. Brazil
8.5.6.1.1. Market size and forecast, by Product
8.5.6.1.2. Market size and forecast, by Technology Type
8.5.6.1.3. Market size and forecast, by Protein Type
8.5.6.1.4. Market size and forecast, by End User
8.5.6.2. Saudi Arabia
8.5.6.2.1. Market size and forecast, by Product
8.5.6.2.2. Market size and forecast, by Technology Type
8.5.6.2.3. Market size and forecast, by Protein Type
8.5.6.2.4. Market size and forecast, by End User
8.5.6.3. South Africa
8.5.6.3.1. Market size and forecast, by Product
8.5.6.3.2. Market size and forecast, by Technology Type
8.5.6.3.3. Market size and forecast, by Protein Type
8.5.6.3.4. Market size and forecast, by End User
8.5.6.4. Rest of LAMEA
8.5.6.4.1. Market size and forecast, by Product
8.5.6.4.2. Market size and forecast, by Technology Type
8.5.6.4.3. Market size and forecast, by Protein Type
8.5.6.4.4. Market size and forecast, by End User
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product mapping of top 10 player
9.4. Competitive dashboard
9.5. Competitive heatmap
9.6. Top player positioning, 2022
CHAPTER 10: COMPANY PROFILES
10.1. Agilent Technologies, Inc.
10.1.1. Company overview
10.1.2. Key executives
10.1.3. Company snapshot
10.1.4. Operating business segments
10.1.5. Product portfolio
10.1.6. Business performance
10.2. Thermo Fisher Scientific Inc.
10.2.1. Company overview
10.2.2. Key executives
10.2.3. Company snapshot
10.2.4. Operating business segments
10.2.5. Product portfolio
10.2.6. Business performance
10.2.7. Key strategic moves and developments
10.3. Promega Corporation
10.3.1. Company overview
10.3.2. Key executives
10.3.3. Company snapshot
10.3.4. Operating business segments
10.3.5. Product portfolio
10.4. New England Biolabs, Inc.
10.4.1. Company overview
10.4.2. Key executives
10.4.3. Company snapshot
10.4.4. Operating business segments
10.4.5. Product portfolio
10.5. Danaher Corporation
10.5.1. Company overview
10.5.2. Key executives
10.5.3. Company snapshot
10.5.4. Operating business segments
10.5.5. Product portfolio
10.5.6. Business performance
10.5.7. Key strategic moves and developments
10.6. Creative Biolabs Limited
10.6.1. Company overview
10.6.2. Key executives
10.6.3. Company snapshot
10.6.4. Operating business segments
10.6.5. Product portfolio
10.7. Bio-Rad Laboratories, Inc.
10.7.1. Company overview
10.7.2. Key executives
10.7.3. Company snapshot
10.7.4. Operating business segments
10.7.5. Product portfolio
10.7.6. Business performance
10.8. Amgen, Inc.
10.8.1. Company overview
10.8.2. Key executives
10.8.3. Company snapshot
10.8.4. Operating business segments
10.8.5. Product portfolio
10.8.6. Business performance
10.8.7. Key strategic moves and developments
10.9. Jena Bioscience GmbH
10.9.1. Company overview
10.9.2. Key executives
10.9.3. Company snapshot
10.9.4. Operating business segments
10.9.5. Product portfolio
10.10. TAKARA HOLDINGS INC.
10.10.1. Company overview
10.10.2. Key executives
10.10.3. Company snapshot
10.10.4. Operating business segments
10.10.5. Product portfolio
10.10.6. Business performance